Skip to Content

Amyvid FDA Approval History

FDA Approved: Yes (First approved April 6, 2012)
Brand name: Amyvid
Generic name: florbetapir F 18
Dosage form: Injection
Company: Eli Lilly and Company and Avid Radiopharmaceuticals, Inc.
Treatment for: Diagnosis and Investigation

Amyvid (florbetapir F 18) is a radioactive diagnostic agent used for brain imaging of beta-amyloid plaques in patients who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

Development Timeline for Amyvid

DateArticle
Apr  9, 2012Approval FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Mar 18, 2011Lilly and Avid Receive Complete Response Letter from FDA for Amyvid (florbetapir F 18 injection)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.